← All trials
NCT05584657
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 18, 2022
- Primary completion
- Mar 15, 2024
- Completion date
- Mar 31, 2024
- First posted
- Oct 18, 2022
- Last posted
- Nov 3, 2022
- Enrollment
- 1966
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Iterum TherapeuticsLead sponsor
- Iterum TherapeuticsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.